SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is heavily trending following record-breaking December and fourth-quarter vehicle deliveries, which are significantly boosting investor optimism about its imminent milestone of one million cumulative cars and its projected path to profitability. The community is actively discussing whether these strong sales, particularly from its premium models and unique battery swap technology, will finally overcome persistent market skepticism and perceived manipulation to drive a substantial valuation rebound in 2026.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe Coin is actively trending amidst strong bullish sentiment across the crypto market, with its community enthusiastically discussing predictions of dropping zeros and even reaching significant price points. Despite some skepticism regarding its fundamentals and large supply, many investors are embracing its meme coin status as a high-risk, high-reward opportunity, fueled by broader 'alt season' narratives.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is trending as a leader in real-world asset tokenization, evidenced by major partnerships with traditional finance players and recent institutional interest following a spot ETF launch. The community views LINK as a long-term utility play, further bolstered by ongoing token accumulation and its proven role as crucial cross-chain infrastructure.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending as traders keenly watch for bullish technical indicators like potential golden crosses and chart breakouts, anticipating significant price movements. The community is largely optimistic, debating whether LTC is poised for a substantial rally, while some express skepticism about its performance as an established altcoin.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is gaining attention due to recent contract wins in space infrastructure and defense, alongside supportive analyst coverage. The community is actively discussing its potential for a short squeeze and 'undervalued' status, anticipating substantial growth as a key player in the expanding space and autonomous systems sectors, fueled by broader industry tailwinds.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending following recent promising open-label data from its FLAMINGO-01 breast cancer trial, which has significantly de-risked the asset. This clinical optimism, amplified by management's extended insider share lock-ups, is driving strong community sentiment around a potential short squeeze due to high borrow costs and tight float. Investors are also actively discussing an impending buyout or partnership, viewing the company as undervalued given its potential in the HER2+ breast cancer market.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is currently trending with high volatility following news of a strategic manufacturing partnership to scale production of its drug screening reader, alongside a significant private placement. While bullish investors view the capital infusion and increased production as catalysts for growth and future market expansion, a strong opposing sentiment is debating the dilutive impact of the share issuance and warrants, suggesting a potential price decline given the stock's recent reverse split and low-float trading characteristics.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad ($MON) is generating significant buzz following its mainnet launch and Coinbase listing, positioning it as a high-performance Layer 1 blockchain with a parallel EVM architecture. Community sentiment is polarized, with many predicting substantial long-term growth and calling it an "X killer," while others express caution regarding its tokenomics, high fully diluted valuation, and potential dilution. The current conversation revolves around its price action, staking opportunities, and how it navigates both positive attention and critical commentary from prominent crypto figures.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital is sparking intense debate as it navigates fresh lows, driven by community concerns over recent share dilution for executive compensation. However, bulls argue the company remains significantly undervalued with its Bitcoin treasury alone exceeding its market cap, anticipating a rebound and potential short squeeze as year-end tax-loss selling concludes and a strategic AI pivot gains traction.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as its primary competitor, Corcept Therapeutics, received a Complete Response Letter from the FDA for its Cushing's syndrome drug, relacorilant. This regulatory setback is seen by the community as a significant tailwind for Xeris's approved treatment, Recorlev, clearing its path to capture greater market share in the expanding Cushing's syndrome market. Investors are actively discussing Recorlev's accelerated growth potential and the anticipated Phase 3 trial for its subcutaneous levothyroxine candidate, XP-8121, as key drivers for future value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven research firms that are currently covering the company...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm...

Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $172,890.12 in Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 5,833 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of...

David Bredt Sells 8,500 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction on Monday, December 15th. The shares were sold at an...

Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $255,170.00 in Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of the firm's stock in a transaction dated Monday, December 15th. The stock was sold at an average...

Wall Street Zen Upgrades Rapport Therapeutics (NASDAQ:RAPP) to Hold

Wall Street Zen raised shares of Rapport Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday...

Rapport Therapeutics (NASDAQ:RAPP) Trading Up 5.4% - Here's Why

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.4% - Time to Buy...

FY2027 Earnings Forecast for RAPP Issued By HC Wainwright

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) - Analysts at HC Wainwright boosted their FY2027 EPS estimates for Rapport Therapeutics in a note issued to investors on Tuesday, December 9th...

Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know 

Does Rapport Therapeutics, Inc. (RAPP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Rapport Therapeutics (NASDAQ:RAPP) Earns Buy Rating from BTIG Research

BTIG Research reaffirmed a "buy" rating and set a $47.00 target price on shares of Rapport Therapeutics in a report on Monday...

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.66	--	--	N/A
Q3 '25	-$0.78	-$0.71	8.39%	BEAT
Q2 '25	-$0.81	-$0.75	7.89%	BEAT
Q1 '25	-$0.76	-$0.68	10.53%	BEAT
Q4 '24	-$0.64	-$0.57	10.99%	BEAT

RAPP
Rapport Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest RAPP News

RAPPRapport Therapeutics Inc